Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia

Published:2012-08-16 Issue:3 Volume:27 Page:635-641
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Denys B,van der Sluijs-Gelling A J,Homburg C,van der Schoot C E,de Haas V,Philippé J,Pieters R,van Dongen J J M,van der Velden V H J

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2012231.pdf

Reference58 articles.

1. Szczepanski T . Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 2007; 21: 622–626.

2. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, van der Velden V, Fischer S et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771–782.

3. Bruggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24: 521–535.

4. Waanders E, van der Velden VH, van der Schoot CE, van Leeuwen FN, van Reijmersdal SV, de Haas V et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011; 25: 254–258.

5. Ryan J, Quinn F, Meunier A, Boublikova L, Crampe M, Tewari P et al. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. Br J Haematol 2009; 144: 107–115.

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia;International Journal of Molecular Sciences;2024-04-30

2. Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?;Blood Cancer Journal;2023-04-24

3. Flow Cytometric MRD Assessment in Acute Lymphoblastic Leukemias;Indian Journal of Medical and Paediatric Oncology;2023-04-17

4. Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy;Cytometry Part B: Clinical Cytometry;2023-03-30

5. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma;International Journal of Hematology;2023-03-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3